S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
S&P 500   4,205.52 (+0.00%)
DOW   33,042.78 (-0.15%)
QQQ   349.98 (+0.45%)
AAPL   177.30 (+1.07%)
MSFT   331.21 (-0.50%)
META   262.52 (+0.18%)
GOOGL   123.67 (-0.75%)
AMZN   121.66 (+1.29%)
TSLA   201.16 (+4.14%)
NVDA   401.11 (+2.99%)
NIO   7.41 (-3.77%)
BABA   78.67 (-2.84%)
AMD   125.27 (-1.39%)
T   15.64 (+0.90%)
F   12.59 (+4.14%)
MU   71.69 (-3.03%)
CGC   0.85 (-3.08%)
GE   102.40 (-0.33%)
DIS   87.82 (-0.53%)
AMC   4.63 (-0.22%)
PFE   37.01 (-1.57%)
PYPL   62.05 (+3.04%)
NFLX   392.98 (+3.72%)
NASDAQ:ECYT

Endocyte (ECYT) Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$23.99
▼
$23.99
50-Day Range
N/A
52-Week Range
$2.81
▼
$24.00
Volume
N/A
Average Volume
2.12 million shs
Market Capitalization
$1.97 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media

ECYT stock logo

About Endocyte (NASDAQ:ECYT) Stock

Endocyte, Inc., a biopharmaceutical company, develops targeted therapies for the treatment of cancer and inflammatory diseases in the United States. The company uses its technology to create novel small molecule drug conjugates (SMDCs) and companion imaging agents. It is developing Vintafolide, a SMDC that is in Phase IIb clinical trial to treat non-small cell lung cancer; EC1456, which is in Phase I dose escalation trial for the treatment of advanced solid tumors; and EC1169, a tubulysin therapeutic that is in Phase I dose escalation trial to treat advanced metastatic castration-resistant prostate cancer. The company's products in pre-clinical development include EC2629, a folate receptor-targeted SMDC for use in treating cancer; EC2319 for the treatment of inflammatory diseases; EC0371 for treating polycystic kidney disease; and SMDC bi-specific adaptor chimeric antigen receptor T-cell for the treatment of immunotherapy in cancer. Endocyte, Inc. has a collaboration agreement with Purdue Research Foundation; Master License Agreement with Purdue Research Foundation; Merck Sharp & Dohme Research GmbH; and Nihon Medi-Physic Co., LTD. The company was founded in 1995 and is headquartered in West Lafayette, Indiana.

Receive ECYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter.

ECYT Stock News Headlines

May 17, 2023 | thestreet.com
The Endocyte Bear Thesis: Why March Will be a Bad Month
January 5, 2023 | thestreet.com
Why Endocyte (ECYT) Stock Is Plummeting in After-Hours Trading Today
May 30, 2023 | Legacy Research (Affiliate) (Ad)
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
September 20, 2022 | finance.yahoo.com
Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Reports Ltd - Yahoo Finance
June 6, 2022 | globenewswire.com
Purdue University impacting lives: successfully delivering innovations to the public - GlobeNewswire
May 23, 2022 | globenewswire.com
Global Chronic Myeloid Leukemia Pipeline Insight | Clinical Trials Evaluation Research Report 2022 by DelveInsight - GlobeNewswire
May 20, 2022 | benzinga.com
Cortexyme Appoints Dr. Philip Low to Its Board of Directors - Benzinga - Benzinga
May 20, 2022 | streetinsider.com
Cortexyme (CRTX) Appoints Philip Low to Its Board - StreetInsider.com
May 30, 2023 | Legacy Research (Affiliate) (Ad)
The “Amazon Secret Royalty Program” Can Help Anyone Retire Like Royalty
A unique type of investment could help you make more money than you will need for the rest of your life. It’s what we call the “Amazon secret royalty program.” It’s an income stream that allows you to collect $1,000s… $10,000s… or more every year! Learn how to collect your first payout before June 13th.
May 3, 2022 | nasdaq.com
Novartis Is Looking for Deals. Are These 3 Biotechs on Its List? - Nasdaq
April 25, 2022 | seekingalpha.com
Clovis: Shifting Toward Nuclear Medicine - Seeking Alpha
April 14, 2022 | globenewswire.com
Global Pharmaceutical Contract Manufacturing Market is projected to reach a market value of US$329.7 Billion in 2032: Visiongain Research Inc - GlobeNewswire
January 31, 2022 | globenewswire.com
Non-Muscle Invasive Bladder Cancer Pipeline Insights | Clinical Trials Report 2022 by DelveInsight - GlobeNewswire
January 27, 2022 | finance.yahoo.com
Global Oncology Radiopharmaceuticals Market to Surpass US$ 5,206.8 Million by 2028, Says Coherent Market Insights (CMI) - Yahoo Finance
December 19, 2021 | proactiveinvestors.com.au
Radiopharm Theranostics enhances management team skillset with three key appointments - Proactive Investors Australia
November 2, 2021 | finance.yahoo.com
Fusion Pharmaceuticals Appoints Industry Veteran Christopher Leamon, Ph.D., as Chief Scientific Officer - Yahoo Finance
November 2, 2021 | streetinsider.com
Fusion Pharmaceuticals Inc. (FUSN) Appoints Christopher Leamon as Chief Scientific Officer - StreetInsider.com
September 20, 2021 | streetinsider.com
Mirati Therapeutics (MRTX) Appoints David Meek as CEO - StreetInsider.com
August 16, 2021 | afr.com
Telix Pharma is on the cusp of first US FDA approval - The Australian Financial Review
July 8, 2021 | wsj.com
Biomedical Companies Inject Innovation Into Cancer Radiotherapy - The Wall Street Journal
June 24, 2021 | nytimes.com
New Therapy for Aggressive Prostate Cancer Improves Survival - The New York Times
June 17, 2021 | nasdaq.com
McDonald's expands loyalty program to some New York City customers - Nasdaq
June 17, 2021 | cnbc.com
Novartis prostate cancer drug receives FDA breakthrough designation - CNBC
June 16, 2021 | nasdaq.com
EXCLUSIVE-Workhorse to challenge USPS decision to award delivery contract to Oshkosh -- source - Nasdaq
June 10, 2021 | prnewswire.com
ACELYRIN Announces Appointment of Patrick Machado, JD to Board of Directors - PRNewswire
June 8, 2021 | prnewswire.com
MorphImmune, Inc., a Research Bridge Partners Portfolio Company, Appoints Ronald Martell as President and CEO - PRNewswire
June 2, 2021 | prnewswire.com
MorphImmune, Inc. Appoints Ronald Martell as President and CEO - PRNewswire
See More Headlines

Receive ECYT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Endocyte and its competitors with MarketBeat's FREE daily newsletter.

ECYT Company Calendar

Last Earnings
11/07/2018
Today
5/30/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical Preparations
Sub-Industry
Pharmaceuticals
Sector
Medical
Current Symbol
NASDAQ:ECYT
CUSIP
29269A10
CIK
1235007
Web
www.endocyte.com
Phone
765-463-7175
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($1.00)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-55,060,000.00
Net Margins
-32,296.09%
Pretax Margin
N/A
Return on Equity
-21.19%
Return on Assets
-20.55%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
45.80
Quick Ratio
45.80

Sales & Book Value

Annual Sales
$70,000.00
Price / Sales
28,133.42
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.99 per share
Price / Book
12.06

Miscellaneous

Outstanding Shares
82,090,000
Free Float
N/A
Market Cap
$1.97 billion
Optionable
Optionable
Beta
-0.01

Key Executives

  • Mr. Michael A. Sherman (Age 52)
    CEO, Pres & Director
  • Mr. Michael T. Andriole (Age 45)
    Chief Financial Officer
  • Dr. Alison A. Armour (Age 54)
    Chief Medical Officer
  • Dr. Christopher P. Leamon (Age 52)
    VP of R&D
  • Dr. Philip S. Low (Age 70)
    Co-Founder, Chief Science Officer & Director

Key Competitors

View All Competitors













ECYT Stock - Frequently Asked Questions

How were Endocyte's earnings last quarter?

Endocyte, Inc. (NASDAQ:ECYT) released its earnings results on Wednesday, November, 7th. The biopharmaceutical company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. The biopharmaceutical company earned $0.09 million during the quarter, compared to analyst estimates of $0.02 million. Endocyte had a negative net margin of 32,296.09% and a negative trailing twelve-month return on equity of 21.19%.

What other stocks do shareholders of Endocyte own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Endocyte investors own include Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Rigel Pharmaceuticals (RIGL), Celldex Therapeutics (CLDX), NVIDIA (NVDA), Synergy Pharmaceuticals (SGYP), Achaogen (AKAO), Bausch Health Companies (BHC) and Inovio Pharmaceuticals (INO).

What is Endocyte's stock symbol?

Endocyte trades on the NASDAQ under the ticker symbol "ECYT."

What is Endocyte's stock price today?

One share of ECYT stock can currently be purchased for approximately $23.99.

How much money does Endocyte make?

Endocyte (NASDAQ:ECYT) has a market capitalization of $1.97 billion and generates $70,000.00 in revenue each year. The biopharmaceutical company earns $-55,060,000.00 in net income (profit) each year or ($1.00) on an earnings per share basis.

How can I contact Endocyte?

Endocyte's mailing address is 3000 KENT AVENUE SUITE A1-100, WEST LAFAYETTE IN, 47906. The official website for the company is www.endocyte.com. The biopharmaceutical company can be reached via phone at 765-463-7175.

This page (NASDAQ:ECYT) was last updated on 5/30/2023 by MarketBeat.com Staff

My Account -